½ÃÀ庸°í¼­
»óÇ°ÄÚµå
1308601

ü¿Ü¸·»ê¼Ò°ø±Þ(ECMO) ±â°è ½ÃÀå ¿¹Ãø(-2030³â) : Á¦Ç°º°, ÄÄÆ÷³ÍÆ®º°, ¸ð´Þ¸®Æ¼º°, ȯÀÚ À¯Çüº°, ¿ëµµº°, Áö¿ªº° ¼¼°è ºÐ¼®

Extracorporeal Membrane Oxygenation Machine Market Forecasts to 2030 - Global Analysis By Product, Component, Modality, Patient Type, Application and By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Stratistics Market Research Consulting | ÆäÀÌÁö Á¤º¸: ¿µ¹® 175+ Pages | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    



¡Ø º» »óÇ°Àº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

Stratistics MRC¿¡ µû¸£¸é, ü¿Ü¸·»ê¼Ò°ø±Þ(ECMO) ±â°è ¼¼°è ½ÃÀåÀº 2023³â 6¾ï 837¸¸ ´Þ·¯·Î ¿¹Ãø ±â°£ µ¿¾È CAGR 7.2%·Î ¼ºÀåÇØ 2030³â 9¾ï 8,976¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ü¿Ü¸·»ê¼Ò°ø±Þ(ECMO) ±â°è´Â ½ÉÀå°ú ÆóÀÇ Á¤»óÀûÀÎ ±â´ÉÀÌ ¼Õ»óµÇ¾î Á¤»óÀûÀΠȣÈíÀ» ÇÒ ¼ö ¾ø´Â ½É°¢ÇÑ ¸»±â ÁúȯÀ» ¾Î°í Àִ ȯÀÚ¿¡°Ô »ç¿ëµÇ´Â »ý¸íÀ¯Áö ±â¼úÀÇ ÀÏÁ¾ÀÔ´Ï´Ù. ½ÉÀå°ú Æó À̽ÄÀ» ±â´Ù¸®´Â ȯÀÚ¸¦ µµ¿ï »Ó¸¸ ¾Æ´Ï¶ó ½ÉÆó ¹ÙÀÌÆнºµµ Áö¿øÇÕ´Ï´Ù. ȯÀÚÀÇ º´¼¼¿¡ µû¶ó ECMO ÀåÄ¡ÀÇ Áö¿øÀº ¸î ½Ã°£¿¡¼­ ¸çÄ¥ µ¿¾È ´Ü±â°£¿¡ ÀÌ·ç¾îÁú ¼öµµ ÀÖ°í, ¸î ÁÖ µ¿¾È Áö¼ÓµÉ ¼öµµ ÀÖ½À´Ï´Ù.

ü¿Ü»ý¸íÀ¯Áö±â±¸¿¡ µû¸£¸é 2016³â 1¿ù, ¾à 8,102¸íÀÇ ¾î¸°ÀÌ°¡ ½ÉÀ庴¿¡ °É·Á ¿¡Å©¸ð Ä¡·á¸¦ ÇÊ¿ä·Î Çß½À´Ï´Ù.

½ÃÀå ¿ªÇÐ:

ÃËÁø¿äÀÎ:

Æó ÀÌ½Ä ¼ö¼ú¿¡¼­ ECMO »ç¿ë Áõ°¡

Æó À̽Ŀ¡ ´ëÇÑ ¼ö¿ä´Â ƯÈ÷ ³¶Æ÷¼º ¼¶À¯Áõ, °£Áú¼º ÆóÁúȯ, ¸¸¼ºÆó¼â¼ºÆóÁúȯ(COPD)°ú °°Àº ¸»±â ÆóÁúȯÀÇ Ä¡·á¸¦ À§ÇØ ¿¹Ãø ±â°£ µ¿¾È Áõ°¡ÇÏ°í ÀÖ½À´Ï´Ù. Æó ÀÌ½Ä ÈÄ ÀÏÂ÷ À̽ÄÆí ±â´ÉºÎÀü(PGD)Àº ¿¡Å©¸ð »ç¿ëÀÇ °¡Àå ºó¹øÇÑ ¿øÀÎÀÔ´Ï´Ù. Æó ÀÌ½Ä ÈÄ 72½Ã°£ À̳»¿¡ ¹ß»ýÇÏ´Â Æó ¼Õ»óÀº PGD ÁõÈıºÀ¸·Î ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù. ÀÌ½Ä ÈÄ PGD ȯÀÚÀÇ Ä¡·á¹ýÀ¸·Î ECMO¸¦ °¡±³ÀûÀ¸·Î »ç¿ëÇÏ´Â °ÍÀº ±â¼úÀÇ »ó´çÇÑ ¹ßÀüÀ¸·Î ÀÎÇØ ´Ù¾çÇÑ ¿¬±¸¿¡¼­ À¯¸ÁÇÑ °á°ú¸¦ °¡Á® ¿Ô½À´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î Æó ÁúȯÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó ECMOÀÇ »ç¿ëÀº ´õ¿í Áõ°¡ÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¾ïÁ¦¿äÀÎ:

ECMO Á¦Ç°ÀÇ ³ôÀº ºñ¿ë

ECMO´Â °í°¡ÀÇ ÀÇ·á ½Ã¼úÀÔ´Ï´Ù. ½Ã½ºÅÛ °ü·Ã ºñ¿ë ¿Ü¿¡µµ º´¿ø ¼÷¹Úºñ, ÀÏȸ¿ë ¾×¼¼¼­¸® µî ±âŸ ºñ¿ëÀÌ ¹ß»ýÇÕ´Ï´Ù. »ç¿ë ±â°£¿¡ µû¶ó ºñ¿ëÀº ´Ù¸£Áö¸¸, ECMO Ä¡·á¸¦ ¹Þ´Â ȯÀÚ¸¦ µ¹º¸´Â µ¥ ¸¹Àº ÀÇ·áÁøÀÌ ÇÊ¿äÇϱ⠶§¹®¿¡ Ä¡·á ºñ¿ëÀÌ Áõ°¡Çϸç, ECMO Áö¿øÀ» ¹Þ´Â ȯÀÚÀÇ ÀϹÝÀûÀÎ ÀÔ¿ø ±â°£Àº 1ÁÖ¿¡¼­ 2ÁÖ Á¤µµÀÌÁö¸¸, ȯÀÚ »óÅÂÀÇ ÁßÁõµµ¿¡ µû¶ó ´õ ±æ¾îÁú ¼öµµ ÀÖ½À´Ï´Ù. ´õ ±æ¾îÁú ¼öµµ ÀÖ½À´Ï´Ù. ±× °á°ú ´ëºÎºÐÀÇ È¯ÀÚ´Â ÀÌ ½Ã¼úÀÇ ÃÑ ºñ¿ëÀ» °¨´çÇÒ ¼ö ¾ø½À´Ï´Ù.

±âȸ:

ECMO·Î ÀÎÇÑ »ýÁ¸À² Çâ»ó

ÁßÁõ ±Þ¼ºÈ£Èí°ï¶õÁõÈıº(ADRS), ÆóÀÌ½Ä ÈÄ ÀÏÂ÷ À̽ÄÆí ±â´ÉºÎÀü, Æó¼Õ»ó µî °¡¿ªÀû °¡´É¼ºÀÌ Àִ ȣÈíºÎÀü ȯÀÚ´Â VV-ECMO·Î Ä¡·áÇØ¾ß Çϸç, VV-ECMO¸¦ ¹ÞÀº È£ÈíºÎÀü ȯÀÚ´Â »ýÁ¸À²ÀÌ ³ô½À´Ï´Ù. Áö¿øÇÒ ¼ö Àֱ⠶§¹®¿¡ ½ÉÀå¿¡ ´ëÇÑ Àû¿ëµµ ÀÌ·ç¾îÁö°í ÀÖ½À´Ï´Ù. ½ÉºÎÀü¿¡ ÀÌ·¯ÇÑ ½Ã½ºÅÛÀ» »ç¿ëÇÑ ½ÉÀ庴 ȯÀÚÀÇ »ýÁ¸À²ÀÌ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù.

À§Çù:

¼÷·ÃµÈ Àü¹® Àη ºÎÁ·

ECMO´Â °íµµ·Î Àü¹®ÀûÀÌ°í º¹ÀâÇÑ Ä¡·á¹ýÀ̸ç, ECMO ÀåÄ¡¸¦ È¿°úÀûÀ¸·Î Á¶ÀÛÇÏ°í °ü¸®ÇÒ ¼ö ÀÖ´Â Àü¹® Áö½ÄÀ» °®Ãá °ü·ù Àü¹®ÀÇ, ÁßȯÀÚ Àü¹®ÀÇ, °£È£»ç, È£Èí Ä¡·á»ç µî ÈÆ·ÃµÈ ÀÇ·á Àü¹®°¡ ÆÀÀÌ ÇÊ¿äÇÕ´Ï´Ù. ±×·¯³ª ¿¡Å©¸ð Àü¹® Áö½Ä°ú ±â¼úÀ» °®Ãá ¼÷·ÃµÈ Àü¹®°¡ÀÇ ¼ö°¡ Á¦ÇѵǾî ÀÖ¾î ¿¡Å©¸ð Ä¡·áÀÇ ±¤¹üÀ§ÇÑ µµÀÔ°ú È°¿ë¿¡ ¾î·Á¿òÀÌ ÀÖÀ¸¸ç, ¿¡Å©¸ð ¼÷·ÃµÈ Àü¹®°¡ÀÇ ºÎÁ·Àº Ä¡·á Á¦°ø¿¡ ¿µÇâÀ» ¹ÌÄ¥ »Ó¸¸ ¾Æ´Ï¶ó ¿¡Å©¸ð ÇÁ·Î±×·¥ È®Àå ¹× ¿¡Å©¸ð ¼¾ÅÍÀÇ ½Å±Ô ¼³¸³À» ¹æÇØÇÏ°í ÀÖ½À´Ï´Ù. ¹æÇØ°¡ µÇ°í ÀÖ½À´Ï´Ù. ÃæºÐÇÑ ¼öÀÇ ¼÷·ÃµÈ Àü¹®°¡°¡ ¾øÀ¸¸é ÀÇ·á ±â°üÀº Àη ºÎÁ·°ú ȯÀÚ Ä¡·áÀÇ ÀúÇϸ¦ ¿ì·ÁÇÏ¿© ECMO Àåºñ¿¡ ´ëÇÑ ÅõÀÚ³ª ECMO ¼­ºñ½º È®ÀåÀ» ÁÖÀúÇÒ ¼ö ÀÖ½À´Ï´Ù.

COVID-19ÀÇ ¿µÇâ:

COVID-19 ÆÒµ¥¹ÍÀ¸·Î ÀÎÇØ Àü ¼¼°è ÀÇ·á ȯ°æÀÌ Å©°Ô º¯È­Çϸ鼭 2020³â ü¿Ü¸·»ê¼Ò°ø±Þ(ECMO) ±â°è ½ÃÀåÀÌ Å©°Ô ¼ºÀåÇß½À´Ï´Ù. ÀÌ´Â ¹ÙÀÌ·¯½º°¡ ±¤¹üÀ§ÇÏ°Ô È®»êµÇ°í ¼øȯ Áö¿øÀ» Á¦°øÇÏ°í »ý¸íÀ» ±¸Çϱâ À§ÇØ ÀÌ·¯ÇÑ ±â°è¿¡ ´ëÇÑ Çʿ伺ÀÌ Áõ°¡Ç߱⠶§¹®À̸ç, COVID-19 ȯÀÚÀÇ Ä¡·á °á°ú°¡ °³¼±µÊ¿¡ µû¶ó º´¿ø¿¡¼­ ü¿Ü¸·»ê¼Ò°ø±Þ(ECMO) ±â°èÀÇ µµÀÔÀÌ Áõ°¡ÇÏ¿© ECMO¿¡ ´ëÇÑ ¼ö¿ä¸¦ ÃËÁøÇÏ°í ÀÖ½À´Ï´Ù. ¼ö¿ä¿¡ ¹ÚÂ÷¸¦ °¡ÇÏ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¼ö¿ä Áõ°¡¿¡ µû¶ó ½ÃÀå °ü°èÀÚµéÀº ÆÒµ¥¹Í ±â°£ µ¿¾È ÀÚ»ç Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡¸¦ ¸ñ°ÝÇß½À´Ï´Ù.

ÆßÇÁ ºÎ¹®Àº ¿¹Ãø ±â°£ µ¿¾È ÃÖ´ë ±Ô¸ðÀÏ °ÍÀ¸·Î ¿¹»ó:

ÆßÇÁ ºÎ¹®µµ ³ôÀº ºñ¿ë°ú »ç¿ë·®À¸·Î ÀÎÇØ »ó´çÇÑ ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÏ°í ÀÖÀ¸¸ç, ECMO ÀåÄ¡ÀÇ ÆßÇÁ´Â ȯÀÚ¿¡°Ô Ç÷¾×À» ´Ù½Ã °ø±ÞÇϱâ Àü¿¡ Àΰø Æó¸¦ ÅëÇØ È¯ÀÚÀÇ Ç÷¾×¿¡ »ê¼Ò¸¦ °ø±ÞÇÏ´Â µ¥ µµ¿òÀ» ÁÖ¸ç, ÆßÇÁ´Â ECMO Ä¡·á¿¡ ³Î¸® »ç¿ëµÇ¸ç, ·Ñ·¯ ÆßÇÁ, ÀÓÆç·¯ ÆßÇÁ, ¿ø½É ÆßÇÁ µî ´Ù¾çÇÑ Á¾·ùÀÇ ÆßÇÁ¸¦ ½±°Ô ±¸ÇÒ ¼ö Àֱ⠶§¹®¿¡ ÀÌ ºÐ¾ß´Â Å©°Ô È®´ëµÇ°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ÆßÇÁ´Â ¼ö¿ä¿¡ µû¶ó ´Ù¾çÇÑ ¿¡Å©¸ð ½Ã¼ú¿¡ äÅõǰí ÀÖÀ¸¸ç, ¿¹Ãø ±â°£ µ¿¾È ÀÌ ºÐ¾ßÀÇ ½ÃÀå È®´ë¿¡ ¹ÚÂ÷¸¦ °¡ÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

¿¹Ãø ±â°£ µ¿¾È °¡Àå ³ôÀº CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â È£Èí±â ºÎ¹®:

¿¹Ãø ±â°£ µ¿¾È ½ÃÀå CAGRÀÌ °¡Àå ³ôÀº ºÎ¹®Àº È£Èí±â ºÎ¹®ÀÔ´Ï´Ù. ´ë»ó ÁúȯÀÇ ±Þ¼ÓÇÑ È®»ê, Á¶±â Áø´Ü ¹× ÀÇ·á °Ë»çÀÇ Á¦ÇÑµÈ °¡¿ë¼º, ü¿Ü¸· »ê¼ÒÈ­ ÀåÄ¡ ½ÃÀåÀÇ ±â¼ú °³¹ß µîÀ¸·Î ÀÎÇØ ½ÃÀåÀÌ È®´ëµÇ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ °áÇÙ°ú °°Àº È£Èí±â Áúȯ, ÈäºÎ ¾Ç¼º ½Å»ý¹°, °ñ´Ù°øÁõ, °ñÀý, CVD À§ÇèÀÎÀÚÀÇ ¹ßº´·ü Áõ°¡·Î ÀÎÇØ Áø´Ü¿ë ÀÇ·á ¿µ»ó Áø´ÜÀÌ È®´ëµÇ°í ÀÖÀ¸¸ç, ÀÌ´Â ÀÌ ºÐ¾ßÀÇ ¼ºÀåÀ» ÃËÁøÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

°¡Àå ³ôÀº Á¡À¯À²À» º¸ÀÌ´Â Áö¿ª:

¿¹Ãø ±â°£ µ¿¾È ºÏ¹Ì°¡ ½ÃÀåÀ» ÁÖµµÇÑ °ÍÀ¸·Î ³ªÅ¸³µ½À´Ï´Ù. ºÏ¹Ì´Â ü¿Ü¸·»ê¼Ò°ø±Þ(ECMO) ±â°èÀÇ Áß¿äÇÑ ½ÃÀåÀ̸ç, ¿©·¯ ÁÖ¿ä ±â¾÷µéÀÌ ÀÌ Áö¿ª¿¡¼­ »ç¾÷À» ¿î¿µÇÏ°í ÀÖ½À´Ï´Ù. ÀÌ Áö¿ªÀÇ ½ÃÀå ¼ºÀåÀº ¾çÁúÀÇ ÀÇ·á ¼­ºñ½º¿¡ ´ëÇÑ Á¤ºÎ Áö¿ø, ³ôÀº ±¸¸Å·Â Æò°¡, ¹Ì±¹ ¹× ij³ª´ÙÀÇ ¸¸¼ºÆó¼â¼ºÆóÁúȯ°ú °°Àº Áúº´ÀÇ À¯º´·ü Áõ°¡¿¡ ±âÀÎÇÕ´Ï´Ù. Á¤±³ÇÑ ÀÇ·á ½Ã¼³ÀÇ Á¸Àç¿Í À¯¸®ÇÑ »óȯ Á¤Ã¥À¸·Î ÀÎÇØ º´¿ø ÀÔ¿øÀ²ÀÌ Áõ°¡ÇÏ¿© ÀÌ Áö¿ªÀÇ »ç¿ë·üÀ» ³ôÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

CAGRÀÌ °¡Àå ³ôÀº Áö¿ª:

¿¹Ãø ±â°£ µ¿¾È ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀåÀº °¡Àå ºü¸¥ ¼Óµµ·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ƯÈ÷ ÀϺ»ÀÇ ³ëÀÎ Àα¸ Áõ°¡, °¡Ã³ºÐ ¼Òµæ Áõ°¡, ÷´Ü ±â¼úÀÇ Àú°¡È­, ´ë»ó ÁúȯÀÇ À¯º´·ü Áõ°¡, Á¤ºÎ Áö¿ø Á¤Ã¥Àº ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ECMO Àåºñ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇÏ´Â ÁÖ¿ä ¿äÀÎÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¿ä¼ÒµéÀº ÀÌ Áö¿ªÀÇ µðÁöÅÐ À̹Ì¡ Àåºñ ½ÃÀåÀ» ÃËÁøÇÏ°í ÇؿܷκÎÅÍÀÇ Çù·Â°ú ÅõÀÚ¸¦ À¯Ä¡ÇÏ°í ÀÖ½À´Ï´Ù. ¹Ý¸é, ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ ½ÃÀå È®´ë´Â ³·Àº º´¿ø ¿¹»ê, °í°¡ÀÇ Àåºñ ºñ¿ë ¹× ÀϺΠ±¹°¡ÀÇ Á¤ºÎ ÁöÃâ ºÎÁ·À¸·Î ÀÎÇØ ´Ù¼Ò ¾ïÁ¦µÇ°í ÀÖ½À´Ï´Ù.

ÁÖ¿ä ¹ßÀü:

  • 2022³â 5¿ù, MicroPort Scientific Corporation, Hemovent GmbH Àμö, Hemovent GmbHÀÇ COVID-19 ȯÀÚ Ä¡·á¿ë MOBYBOX ECMO ½Ã½ºÅÛÀÌ ÁÖ¿ä ±¹Á¦ ÀÇÇÐ Àú³ÎÀÎ ASAIO Journal¿¡ °ÔÀçµÊ.
  • LivaNova PLC, 2022³â 11¿ù LifeSPARC¿¡ ´ëÇÑ FDA ½ÂÀÎ ¹ßÇ¥, Â÷¼¼´ë ÷´Ü ¼øȯ º¸Á¶ ½Ã½ºÅÛ 510(k) ½ÂÀΠȹµæ
  • 2021³â 10¿ù, MicroPort Scientific CorporationÀÌ µ¶ÀÏ Ã¼¿Ü»ý¸íÀ¯ÁöÀåÄ¡(ECLS) ±â¾÷ Hemovent GmbH¸¦ ÀμöÇØ µ¶ÀÏ »ç¾÷ È®Àå¿¡ ÅõÀÚ
  • 2021³â 7¿ù, Xenios AG, Áß±¹ ±¹°¡ÀÇ·áÁ¦Ç°°¨µ¶°ü¸®±¹(NMPA)À¸·ÎºÎÅÍ ECMO Ä¡·á¿ë Á¦´Ï¿À½º ÄÜ¼Ö ¹× ȯÀÚ Å°Æ® ½ÂÀΠȹµæ

º¸°í¼­ ³»¿ë

  • Áö¿ª ¹× ±¹°¡ ¼öÁØ ºÎ¹® ½ÃÀå ¼¼ºÐÈ­
  • ½Å±Ô ÁøÀÔ±â¾÷¿¡ ´ëÇÑ Àü·«Àû Á¦¾ð
  • 2021³â, 2022³â, 2023³â, 2026³â, 2030³â ½ÃÀå µ¥ÀÌÅ͸¦ Æ÷ÇÔ
  • ½ÃÀå µ¿Çâ
  • ½ÃÀå ÃßÁ¤¿¡ ±â¹ÝÇÑ ÁÖ¿ä »ç¾÷ ºÎ¹®¿¡ ´ëÇÑ Àü·«Àû Á¦¾ð
  • ÁÖ¿ä °øÅë Æ®·»µå¸¦ ¸ÅÇÎÇÑ °æÀï »óȲ
  • »ó¼¼ÇÑ Àü·«, À繫 ¹× ÃÖ±Ù µ¿ÇâÀ» Æ÷ÇÔÇÑ ±â¾÷ °³¿ä
  • ÃֽŠ±â¼ú µ¿ÇâÀ» ¸ÅÇÎÇÑ °ø±Þ¸Á Æ®·»µå

¹«·á ¸ÂÃãÇü ¼­ºñ½º:

ÀÌ º¸°í¼­¸¦ ±¸µ¶ÇÏ´Â °í°´¿¡°Ô´Â ´ÙÀ½ Áß ÇϳªÀÇ ¹«·á ¸ÂÃãÈ­ ¿É¼ÇÀ» Á¦°øÇÕ´Ï´Ù:

  • ±â¾÷ °³¿ä
    • Ãß°¡ ½ÃÀå ±â¾÷ÀÇ Á¾ÇÕÀûÀÎ ÇÁ·ÎÆÄÀϸµ(ÃÖ´ë 3°³»ç±îÁö)
    • ÁÖ¿ä ±â¾÷ SWOT ºÐ¼®(3°³»ç±îÁö)
  • Áö¿ª ¼¼ºÐÈ­
    • °í°´ÀÇ °ü½É¿¡ µû¸¥ ÁÖ¿ä ±¹°¡º° ½ÃÀå ÃßÁ¤ ¹× ¿¹Ãø, CAGR(Âü°í: Ÿ´ç¼º °ËÅä¿¡ µû¸¥)
  • °æÀï»ç º¥Ä¡¸¶Å·
    • Á¦Ç° Æ÷Æ®Æú¸®¿À, Áö¸®Àû ÀÔÁö, Àü·«Àû Á¦ÈÞ¸¦ ±â¹ÝÀ¸·Î ÇÑ ÁÖ¿ä ±â¾÷ º¥Ä¡¸¶Å·

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ¼­¹®

  • ÁÖ¿ä ¿ä¾à
  • ÀÌÇØ°ü°èÀÚ
  • Á¶»ç ¹üÀ§
  • Á¶»ç ¹æ¹ý
    • µ¥ÀÌÅÍ ¸¶ÀÌ´×
    • µ¥ÀÌÅÍ ºÐ¼®
    • µ¥ÀÌÅÍ °ËÁõ
    • Á¶»ç Á¢±Ù¹ý
  • Á¶»ç ¼Ò½º
    • 1Â÷ Á¶»ç Á¤º¸ Ãâó
    • 2Â÷ Á¶»ç Á¤º¸ Ãâó
    • °¡Á¤

Á¦3Àå ½ÃÀå µ¿Ç⠺м®

  • ¼ºÀå ÃËÁø¿äÀÎ
  • ¼ºÀå ¾ïÁ¦¿äÀÎ
  • ±âȸ
  • À§Çù
  • Á¦Ç° ºÐ¼®
  • ¿ëµµ ºÐ¼®
  • ½ÅÈï ½ÃÀå
  • COVID-19ÀÇ ¿µÇâ

Á¦4Àå Porter's Five Forces ºÐ¼®

  • °ø±Þ ±â¾÷ÀÇ ±³¼··Â
  • ±¸¸ÅÀÚÀÇ ±³¼··Â
  • ´ëüǰÀÇ À§Çù
  • ½Å±Ô Âü¿©¾÷üÀÇ À§Çù
  • °æÀï ±â¾÷°£ °æÀï °ü°è

Á¦5Àå ü¿Ü¸·»ê¼Ò°ø±Þ(ECMO) ¼¼°è ½ÃÀå : Á¦Ç°º°

  • ÈÞ´ë¿ë µð¹ÙÀ̽º
  • °íÁ¤ µð¹ÙÀ̽º
  • ¼ÒÇÁÆ®¿þ¾î
  • ±âŸ Á¦Ç°

Á¦6Àå ü¿Ü¸·»ê¼Ò°ø±Þ(ECMO) ¼¼°è ½ÃÀå : ÄÄÆ÷³ÍÆ®º°

  • ÆßÇÁ
  • »ê¼Ò°ø±Þ±â
  • ÄÁÆ®·Ñ·¯
  • ij´¼¶ó
  • È£Èí ¾×¼¼¼­¸®
  • ±âŸ ÄÄÆ÷³ÍÆ®

Á¦7Àå ü¿Ü¸·»ê¼Ò°ø±Þ(ECMO) ¼¼°è ½ÃÀå : ¸ð´Þ¸®Æ¼º°

  • Á¤¸Æ-Á¤¸Æ
  • Á¤¸Æ-µ¿¸Æ
  • µ¿¸Æ-Á¤¸Æ
  • ±âŸ ¸ð´Þ¸®Æ¼

Á¦8Àå ü¿Ü¸·»ê¼Ò°ø±Þ(ECMO) ¼¼°è ½ÃÀå : ȯÀÚ À¯Çüº°

  • ½Å»ý¾Æ
  • ¼Ò¾Æ
  • ¼ºÀÎ

Á¦9Àå ü¿Ü¸·»ê¼Ò°ø±Þ(ECMO) ¼¼°è ½ÃÀå : ¿ëµµº°

  • È£Èí±â
  • ½ÉÀå
  • ü¿Ü ½ÉÆó ¼Ò»ý(ECPR)
  • ½ÉÆó ¼Ò»ý(CPR)
  • ¼±Ãµ¼º ½ÉÁúȯ
  • ÀÌ½Ä Áß°³
  • ±âŸ ¿ëµµ

Á¦10Àå ü¿Ü¸·»ê¼Ò°ø±Þ(ECMO) ¼¼°è ½ÃÀå : Áö¿ªº°

  • ºÏ¹Ì
    • ¹Ì±¹
    • ij³ª´Ù
    • ¸ß½ÃÄÚ
  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÀÌÅ»¸®¾Æ
    • ÇÁ¶û½º
    • ½ºÆäÀÎ
    • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ÀϺ»
    • Áß±¹
    • Àεµ
    • È£ÁÖ
    • ´ºÁú·£µå
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • ³²¹Ì
    • ¾Æ¸£ÇîƼ³ª
    • ºê¶óÁú
    • Ä¥·¹
    • ±âŸ ³²¹Ì
  • Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®
    • īŸ¸£
    • ³²¾ÆÇÁ¸®Ä«°øÈ­±¹
    • ±âŸ Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«

Á¦11Àå ÁÖ¿ä ¹ßÀü

  • °è¾à, ÆÄÆ®³Ê½Ê, Á¦ÈÞ, ÇÕÀÛÅõÀÚ
  • Àμö¿Í ÇÕº´
  • ½ÅÁ¦Ç° Ãâ½Ã
  • »ç¾÷ È®´ë
  • ±âŸ ÁÖ¿ä Àü·«

Á¦12Àå ±â¾÷ °³¿ä

  • ABIOMED
  • EUROSETS
  • Getinge AB
  • LivaNova PLC
  • MAQUET Holding B.V. & Co. KG
  • Medos Medizintechnik AG
  • Medtronic
  • Microport Scientific Corporation
  • Nipro Medical Corporation
  • Sorin Group
  • Spectrum Medical
  • Terumo Cardiovascular Systems Corporation
  • Xenios AG
ksm 23.08.08

According to Stratistics MRC, the Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market is accounted for $608.37 million in 2023 and is expected to reach $989.76 million by 2030 growing at a CAGR of 7.2% during the forecast period. Extracorporeal membrane oxygenation is a type of life-supporting technology used for individuals with severe, terminal illnesses that impair their heart's or lungs' ability to function normally and keep them from breathing normally. In addition to helping those awaiting a heart or lung transplant, this mechanism offers heart-lung bypass support. Depending on the patient's medical state, ECMO machine support may be given for a short period of time-a few hours or days-or it may last for a few weeks.

According to the Extracorporeal Life Support Organization, in January 2016, around 8,102 children suffered from cardiac illness and required ECMO therapy.

Market Dynamics:

Driver:

Increasing use of ECMO in lung transplant procedures

The need for lung transplants has grown over the forecast period, particularly for the treatment of terminal lung conditions such as cystic fibrosis, Interstitial Lung Disease, and Chronic Obstructive Pulmonary Disease (COPD). Primary Graft Dysfunction (PGD) after lung transplantation is the most frequent cause for the use of ECMO. Lung damage that occurs within the first 72 hours after a lung transplant is known as PGD syndrome. The use of ECMO as a bridging method as a treatment for patients with PGD post-transplant has produced promising results in various studies thanks to considerable technological advancements. The use of ECMO is anticipated to increase further due to the rising prevalence of lung disorders worldwide.

Restraint:

High cost of ECMO products

ECMO is an expensive medical procedure. In addition to the expenditures related to the systems, there are other charges such as hospital lodging and extra disposable accessories. The cost of the treatment increases with the need for a large medical staff to care for the patient receiving an ECMO procedure, although the cost varies depending on how long it is used. The typical hospital stay for a patient receiving ECMO support is between one and two weeks, though it might vary depending on how serious the patient's condition is and last longer. The majority of patients cannot afford the procedure's higher overall cost as a result.

Opportunity:

Increasing survival rates with ECMO

Patients with potentially reversible respiratory failure, such as those with severe acute respiratory distress syndrome (ADRS), primary graft dysfunction following lung transplantation, and lung injury, should be treated with VV-ECMO. Patients with respiratory failure who receive VV-ECMO have a higher survival rate. Due to their capability to support failing circulatory systems with oxygenation functions, ECMO machines are also used in cardiac applications. The survival rates of cardiac patients who use these systems for heart failure are increased.

Threat:

Lack of skilled professionals

ECMO is a highly specialized and complex therapy that requires a team of trained healthcare professionals, including perfusionists, intensivists, nurses, and respiratory therapists, who possess the expertise to operate and manage ECMO machines effectively. However, the limited availability of trained professionals with ECMO-specific knowledge and skills poses challenges to the broader adoption and utilization of ECMO therapy. The lack of skilled professionals in ECMO not only affects the delivery of therapy but also impedes the expansion of ECMO programs and the establishment of new ECMO centers. Without a sufficient number of trained professionals, healthcare facilities may be hesitant to invest in ECMO machines or expand their ECMO services, fearing inadequate staffing and compromised patient care.

COVID-19 Impact::

The COVID-19 pandemic has significantly changed the landscape of healthcare practices worldwide and resulted in considerably high growth of the extracorporeal membrane oxygenation machine market in 2020. This is attributed to the vast spread of the virus and the increasing need for these machines to provide circulatory support and save lives. The improved machine outcome in COVID-19 patients led to increased adoption of these machines in hospitals, thereby fueling the demand for extracorporeal membrane oxygenation machines. Owing to the rise in demand, market players witnessed increased demand for their products during the pandemic.

The pumps segment is expected to be the largest during the forecast period:

The pumps segment also has a considerable market share owing to its high cost and usage. The ECMO machines' pumps assist in moving a patient's blood through artificial lungs for oxygenation before returning the blood to the patient. Due to the widespread use of pumps in ECMO treatments and the accessibility of many types of pumps, including roller, impeller, and centrifugal pumps, the segment has experienced significant expansion. According to their requirements, these pumps are employed in a variety of ECMO procedures, which will fuel the market expansion of this sector throughout the forecasted time.

The respiratory segment is expected to have the highest CAGR during the forecast period:

The respiratory segment has the highest CAGR in the market over the forecast period. The market is expanding due to the rapid spread of the target diseases, the limited availability of early diagnosis and medical testing, and technological developments in the Extracorporeal Membrane Oxygenation Machine Market. Diagnostic medical imaging is also expanding due to the rising incidence of respiratory diseases like tuberculosis, thorax malignant neoplasms, osteoporosis, broken bones, and CVD risk factors, which will propel the segment's growth.

Region with highest share:

North America dominated the market over the forecast period. North America is a significant market for Extracorporeal Membrane Oxygenation (ECMO) Machines, with several prominent players operating in the region. The growth of this market in the region can be attributed to the government support for quality healthcare, high purchasing power parity, and the increasing prevalence of diseases such as chronic obstructive pulmonary disease in the U.S. and Canada. The presence of sophisticated healthcare facilities and favorable reimbursement policies has led to an increased hospital admission rate which in turn is expected to boost the usage rates in this region.

Region with highest CAGR:

During the forecast period, the Asia Pacific market is anticipated to grow at the fastest rate. The rising geriatric population, especially in Japan, rising disposable incomes, making more advanced technologies affordable, the rising prevalence of target diseases, and supportive government initiatives are the main drivers of the ECMO machine market's growth in the Asia Pacific region. These elements propel the regional market for digital imaging equipment and draw in collaborations and investments from abroad. On the other hand, the expansion of the market in the Asia Pacific is being somewhat constrained by low hospital budgets, expensive equipment costs, and a lack of government expenditures in some nations.

Key players in the market

Some of the key players in Extracorporeal Membrane Oxygenation (ECMO) Machine Market include ABIOMED, EUROSETS, Getinge AB, LivaNova PLC, MAQUET Holding B.V. & Co. KG, Medos Medizintechnik AG, Medtronic, Microport Scientific Corporation, Nipro Medical Corporation, Sorin Group, Spectrum Medical, Terumo Cardiovascular Systems Corporation and Xenios AG.

Key Developments:

  • In May 2022, MicroPort Scientific Corporation acquired Hemovent GmbH and Hemovent GmbH's MOBYBOX ECMO System for the Treatment of COVID-19 Patients Published in Leading International Medical Journal-ASAIO Journal
  • In November 2022, LivaNova PLC announced the FDA clearance for LifeSPARC. The company received 510(k) approval for its next-generation advanced circulatory support system
  • In October 2021, MicroPort Scientific Corporation acquired German Extracorporeal life support (ECLS) company Hemovent GmbH and invested in expanding the company's German operations
  • In July 2021, Xenios AG received approval from the National Medical Products Administration (NMPA) in China for the Xenios Console and patient kits for ECMO therapy

Products Covered:

  • Portable Devices
  • Static Devices
  • Software
  • Other Products

Components Covered:

  • Pumps
  • Oxygenators
  • Controllers
  • Cannul a
  • Breathing Accessories
  • Other Components

Modalities Covered:

  • Veno-Venous
  • Veno-Arterials
  • Arterio-Venous
  • Other Modalities

Patient Types Covered:

  • Neonates
  • Pediatrics
  • Adults

Applications Covered:

  • Respiratory
  • Cardiac
  • Extracorporeal Cardiopulmonary Resuscitation (ECPR)
  • Cardiopulmonary Resuscitation (CPR)
  • Congenital Heart Defects
  • Bridge to Transplantation
  • Other Applications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2021, 2022, 2023, 2026 and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Product Analysis
  • 3.7 Application Analysis
  • 3.8 Emerging Markets
  • 3.9 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market, By Product

  • 5.1 Introduction
  • 5.2 Portable Devices
  • 5.3 Static Devices
  • 5.4 Software
  • 5.5 Other Products

6 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market, By Component

  • 6.1 Introduction
  • 6.2 Pumps
  • 6.3 Oxygenators
  • 6.4 Controllers
  • 6.5 Cannula
  • 6.6 Breathing Accessories
  • 6.7 Other Components

7 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market, By Modality

  • 7.1 Introduction
  • 7.2 Veno-Venous
  • 7.3 Veno-Arterials
  • 7.4 Arterio-Venous
  • 7.5 Other Modalities

8 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market, By Patient Type

  • 8.1 Introduction
  • 8.2 Neonates
  • 8.3 Pediatrics
  • 8.4 Adults

9 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market, By Application

  • 9.1 Introduction
  • 9.2 Respiratory
  • 9.3 Cardiac
  • 9.4 Extracorporeal cardiopulmonary resuscitation (ECPR)
  • 9.5 Cardiopulmonary Resuscitation (CPR)
  • 9.6 Congenital Heart Defects
  • 9.7 Bridge to Transplantation
  • 9.8 Other Applications

10 Global Extracorporeal Membrane Oxygenation (ECMO) Machine Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 ABIOMED
  • 12.2 EUROSETS
  • 12.3 Getinge AB
  • 12.4 LivaNova PLC
  • 12.5 MAQUET Holding B.V. & Co. KG
  • 12.6 Medos Medizintechnik AG
  • 12.7 Medtronic
  • 12.8 Microport Scientific Corporation
  • 12.9 Nipro Medical Corporation
  • 12.10 Sorin Group
  • 12.11 Spectrum Medical
  • 12.12 Terumo Cardiovascular Systems Corporation
  • 12.13 Xenios AG
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óÇ°À» ¼±Åà Áß
»óÇ° ºñ±³Çϱâ
Àüü»èÁ¦